Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "revenue-growth"

170 News Found

Axol Bioscience acquires ophthalmology business from Newcells Biotech
News | February 19, 2026

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models


IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
News | February 13, 2026

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY


Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics
News | February 13, 2026

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore


SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
News | February 10, 2026

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%


Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
News | February 09, 2026

Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive

The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses


Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
News | February 06, 2026

Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY

On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY


AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth
News | February 05, 2026

AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth

Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,


Hester Biosciences posts strong Q3 profit surge as poultry business powers growth
News | February 02, 2026

Hester Biosciences posts strong Q3 profit surge as poultry business powers growth

The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period


Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
News | February 02, 2026

Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY

Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%